For instance, CP-640186, an effective inhibitor of mammalian ACCs targeting the CT domain, has been shown to reduce body fat mass and improve insulin sensitivity, underscoring the potential of ACCs in anti-obesity and anti-diabetes therapies (6, 7). This evidence concerns the gene ACCS and obesity due to melanocortin 4 receptor deficiency.